BioSpace News Archive

Akoya Biosciences, Inc., The Spatial Biology Company®, announced they are partnering with Enable Medicine to introduce a cloud platform capable of significantly accelerating the analysis of high plex spatial image datasets generated by Akoya’s PhenoCycler-Fusion system.

Kala Pharmaceuticals, Inc. (NASDAQ:KALA) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Kala’s human mesenchymal stem cell secretome (MSC-S) therapy (KPI-012) for the treatment of persistent corneal epithelial defect (PCED), a rare and debilitating ocular condition.

Beacon Biosignals today announced it has named biotechnology industry veteran Christine Vietz, Ph.D., as Chief Research and Development Officer.

Agilent Technologies Inc. (NYSE: A) today announced a strategic partnership with PathAI, a leading provider of AI-powered research tools and services for pathology, to deliver biopharmaceutical organizations a solution that combines Agilent’s assay development expertise and PathAI’s algorithm development capabilities.

Visus Therapeutics Inc. today announced Jehan Tamboowalla joined the company as senior vice president of business development and marketing.

Neocis®, manufacturer of Yomi® and the global leader in robot-assisted dental surgery, announced the official market launch of the platform’s bone reduction module.

Navrogen, Inc. will be presenting new preclinical data on its NAV-001 antibody-drug conjugate (ADC) and NAV-003 bispecific programs at the 2023 American Association for Cancer Research (AACR) Conference in Orlando, Florida on April 17 and 18.

DBV Technologies, a clinical-stage biopharmaceutical company, held its Ordinary and Extraordinary General Meeting.

Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, will release its financial results for the first quarter 2023 after market close on Tuesday, May 2, 2023.

GlucoTrack, Inc., a medical device and digital health platform company focused on diabetes and prediabetes, announced that it intends to offer shares of common stock in a firm commitment underwritten public offering.